Litcius/Paper detail

YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells

Hui Hu, Xiaokang Miao, Jingyi Li, Xiaowei Zhang, Jingjie Xu, Jingying Zhang, Tianxiong Zhou, Ming-Ning Hu, Wenle Yang, Lingyun Mou

2020European Journal of Pharmacology41 citationsDOI

Topics & Concepts

GefitinibCancer researchProtein kinase BEpidermal growth factor receptorTyrosine kinaseTyrosine-kinase inhibitorEGFR inhibitorsPharmacologyMedicineSignal transductionChemistryCancerInternal medicineBiochemistryGlycosylation and Glycoproteins ResearchLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells | Litcius